首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1624410

全球細胞裂解/細胞分餾市場規模（按細胞類型、最終用戶、產品、地區、範圍和預測）

Global Cell Lysis/Cell Fractionation Market Size By Type Of Cell, By End User, By Product, By Geographic Scope And Forecast

出版日期: 2024年09月05日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

細胞裂解/細胞分離的市場規模與預測

細胞裂解/細胞分餾市場規模預計在 2023 年達到 45.5 億美元，到 2030 年將達到 63 億美元，2024 年至 2030 年的複合年增長率為 7.2%。該市場的成長歸因於用於商業診斷和分析應用的細胞培養程序的數量不斷增加。預計整個預測期內各種疾病盛行率的持續上升和對新療法的需求將推動市場擴張。此外，由於各種慢性和非慢性疾病發病率上升導致細胞生物學研究的進步和對蛋白質分析的需求增加，預計將對市場成長產生積極影響。

定義全球細胞裂解/細胞分離市場

細胞裂解/細胞分離是細胞生物學中應用的相關技術，用於打開和分離細胞及其成分。細胞裂解是指細胞破裂並釋放其內部成分，如核酸、蛋白質和細胞器。細胞打開可以透過化學方法、機械方法或酵素方法來實現。細胞裂解是多種研究應用中不可或缺的步驟，包括藥物開發、蛋白質純化和 DNA 分離。

細胞分離是裂解後細胞不同成分的分離。該過程透過密度梯度離心、差速離心和其他分離亞細胞或特定細胞器的方法完成。所得材料部分可用於進一步分析。

全球細胞裂解/細胞分離市場概述

民眾對個人化醫療的需求不斷增長是市場的主要驅動力。個人化醫療具有多種優勢，包括客製化治療、更早發現疾病、降低醫療成本、改善藥物開發和更有效率的臨床試驗。個人化醫療允許醫療專業人員根據患者的情況制定治療方案。治療是基於生活方式、特定的遺傳傾向和其他因素。這些因素有助於改善治療結果並降低藥物副作用的風險。細胞裂解應用於個人化醫療，以提取和分離與患者治療或診斷相關的特定分子或細胞類型。

公共和私人機構對生命科學研究的投資不斷增加預計將對市場成長產生積極影響。例如，2023年3月，英國政府宣佈撥款2.77億英鎊，其中政府將出資1,700萬英鎊。剩餘的 2.6 億英鎊將透過對生命科學製造計畫的私人投資來提供，以最大限度地減少對環境的影響，增強健康的復原力，並部署創新以促進國家的發展。這筆資金預計將在全國創造500多個就業崗位，支持該國的經濟。

此外，癌症、糖尿病、心血管疾病和關節炎等慢性病的日益普及預計將對市場成長產生積極影響。細胞裂解和分餾是診斷慢性疾病的關鍵步驟。例如，在診斷類風濕性關節炎等自體免疫疾病時，可以利用細胞裂解法從患者血液中分離自體免疫細胞，並提取 DNA 或 RNA 進行基因表現分析。此步驟可以識別免疫細胞中過度表達或表達不足的特定蛋白質或基因，這有助於診斷疾病和開發個人化藥物。

概述
北美
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 亞太其他地區
拉丁美洲
- 巴西
- 阿根廷
- 其他拉丁美洲
中東/非洲
- 阿拉伯聯合酋長國
- 沙烏地阿拉伯
- 南非
- 其他中東和非洲

第9章全球細胞裂解/細胞分餾市場：競爭格局

概述
各公司市場排名
主要發展策略
公司區域足跡
按行業劃分的企業足跡
ACE矩陣

第10章公司簡介

Thermo Fisher Scientific Inc.
Merck KGAA
Bio-Rad Laboratories, Inc.
Beckman Coulter, Inc.
Becton, Dickinson, and Company
Cell Signaling Technology, Inc.
MiltenyiBiotec
Roche Diagnostics
Qiagen N.V.
Qsonica有限公司

第11章重大進展

產品發佈/開發
併購
業務拓展
夥伴關係和聯盟

第 12 章附錄

相關研究

簡介目錄

Product Code: 24222

Cell Lysis/Cell Fractionation Market Size And Forecast

Cell Lysis/Cell Fractionation Market size was valued at USD 4.55 Billion in 2023 and is calculated to reach USD 6.3 Billion by 2030, expanding at a CAGR of 7.2% from 2024 to 2030. The market's growth is attributed to the growing number of cultured cell procedures used for commercial diagnostic and analytical applications. The continued rise in the prevalence of various ailments and the demand for novel therapies are projected to drive market expansion throughout the forecast period. Additionally, the growing advances in cell biology research and increased demand for protein analysis due to the increasing prevalence of various chronic and non-chronic conditions are expected to positively influence the market's growth.

Global Cell Lysis/Cell Fractionation Market Definition

Cell lysis and fractionation are related techniques that have applications in cell biology to open and separate cells and their components. Cell lysis refers to breaking the cells open to release the components in the cell, such as nucleic acid, proteins, and cell organelles. The cell's opening is done chemically, mechanically, or enzymatically. Cell lysis is an essential step in several research applications, such as drug development, protein purification, and DNA isolation.

Cell fractionation refers to separating different components of the cell after lysis. The process is carried out through density gradient centrifugation, differential centrifugation, and other methods to isolate subcellular or specific organelles. The fractions of the obtained materials can then be used for further analysis.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Cell Lysis/Cell Fractionation Market Overview

The growing demand for personalized medicine among the population is a key driver for the market. Personalized medicine offers several advantages, such as tailored treatments, early disease detection, reduced healthcare costs, improved drug development, and more efficient clinical trials. Personalized medicines allow healthcare professionals to provide tailored treatment to patients. The treatment is based on lifestyle, specific genetic makeup, and other factors; these factors help to improve the treatment outcomes and reduce the risk of side effects of the drugs. Cell lysis has applications in personalized medicines for extracting and isolating specific molecules or cell types relevant to a patient's treatment and diagnosis.

Growing investments by public and private institutions for research in life sciences are anticipated to impact market growth positively. For instance, in March 2023, the UK government announced funding of GBP 277 Million, wherein the government will contribute GBP 17 Million. The remaining 260 million will be provided through private investments for life science manufacturing projects, minimizing environmental impact, boosting health resilience, and deploying innovations, contributing to the country's growth. The funding is anticipated to support the country's economy by providing more than 500 jobs nationwide.

Additionally, the increasing prevalence of chronic conditions such as cancer, diabetes, cardiovascular diseases, and arthritis, among others, is expected to impact the market growth positively. Cell lysis and fractionation are key steps used to diagnose chronic conditions. For example, diagnosis of autoimmune diseases such as rheumatoid arthritis and cell lysis can be used to isolate autoimmune cells from the patient's blood and extract the DNA or RNA for gene expression analysis. The step helps identify specific proteins and genes that are either over or under-expressed in the immune cells, helping diagnose the disease and develop personalized medicine.

Global Cell Lysis/Cell Fractionation Market: Segmentation Analysis

The Global Cell Lysis/Cell Fractionation Market is Segmented on the basis of Type Of Cell, End User, Product, and Geography.

Cell Lysis/Cell Fractionation Market, By Type Of Cell

Mammalian Cells
Microbial Cells
Others

Based on Type Of Cell, the market is bifurcated into Mammalian Cells, Microbial Cells, and Others. The mammalian cells segment accounted for the highest share in 2022 and is calculated to grow lucratively during the forecast period. The applications of these cells for the bio-manufacturing of vaccines, therapeutic proteins, and other recombinant products are key factors driving the segment's growth.

Cell Lysis/Cell Fractionation Market, By End User

Research Laboratories and Institutes
Biopharmaceutical and Biotechnology Companies
Others

Based on End User, the market is bifurcated into Research Laboratories and Institutes, Biopharmaceutical and Biotechnology Companies, and Others. The Research Laboratories and Institutes segment held the largest market share in 2022 and is calculated to grow lucratively during the forecast period. The growing number of biotechnology institutes and many research activities undertaken by these institutes are driving the market's growth.

Cell Lysis/Cell Fractionation Market, By Product

Instruments
Sonicator
Homogenizers
Other Instruments
Consumables
Reagents and Kits
Beads
Disposables

Based on Product, the market is bifurcated into Instruments and Consumables. Instruments are classified into sonicators, homogenizers, and other instruments. Consumables are further differentiated into reagents & kits, beads, and disposables. The consumables segment accounted for the highest share in 2022 and is projected to grow lucratively during the forecast period. Repeated purchases, increased funding for cell-based research activities, and the increasing instances of chronic conditions among the population are factors driving the segment's growth.

Cell Lysis/Cell Fractionation Market, By Geography

North America
Europe
Asia Pacific
Middle East and Africa
Latin America
On the basis of Regional Analysis, The Global Cell Lysis/Cell Fractionation Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. North America held the highest share in 2022 and is projected to grow lucratively during the forecast period owing to the technologically advanced R&D infrastructure. Moreover, the regional governments are also providing funding for the development of infrastructure and research projects, which is expected to impact market growth positively.

Key Players

The "Global Cell Lysis/Cell Fractionation Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Thermo Fisher Scientific Inc., Merck KGAA, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Becton, Dickinson and Company, Cell Signaling Technology, Inc., MiltenyiBiotec, Roche Diagnostics, Qiagen N.V., and Qsonica, LLC., among others.
This section provides a company overview, ranking analysis, company regional and industry footprint, and ACE Matrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

In November 2022, Merck announced it would acquire Imago BioSciences Inc. The acquisition will help Merck to gain an edge over its competitors for clinical development.
Ace Matrix Analysis
The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as
Active, Cutting Edge, Emerging, and Innovators.
Market Attractiveness
The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Cell Lysis/Cell Fractionation Market. We cover the major impacting factors driving the industry growth in the given region.
Porter's Five Forces
The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the Global Cell Lysis/Cell Fractionation Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

1 INTRODUCTION OF THE GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porter's Five Force Model
4.4 Value Chain Analysis

5 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY TYPE OF CELL

6.1 Overview
6.2 Mammalian Cells
6.3 Microbial Cells
6.4 Others

6 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY END USER

7.1 Overview
7.2 Research Laboratories and Institutes
7.3 Biopharmaceutical and Biotechnology Companies
7.4 Others

7 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY PRODUCT

7.1 Overview
7.2 Instruments
- 7.2.1 Sonicator
- 7.2.2 Homogenizers
- 7.2.3 Other Instruments
7.3 Consumables
- 7.3.1 Reagents and Kits
- 7.3.2 Beads
- 7.3.3 Disposables

8 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET, BY GEOGRAPHY

8.1 Overview
8.2 North America
- 8.2.1 The U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
8.3 Europe
- 8.3.1 Germany
- 8.3.2 The U.K.
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Argentina
- 8.5.3 Rest of LATAM
8.6 Middle East and Africa
- 8.6.1 UAE
- 8.6.2 Saudi Arabia
- 8.6.3 South Africa
- 8.6.4 Rest of the Middle East and Africa

9 GLOBAL CELL LYSIS/CELL FRACTIONATION MARKET COMPETITIVE LANDSCAPE

9.1 Overview
9.2 Company Market Ranking
9.3 Key Development Strategies
9.4 Company Regional Footprint
9.5 Company Industry Footprint
9.6 ACE Matrix

10 COMPANY PROFILES

10.1 Thermo Fisher Scientific Inc.
- 10.1.1 Company Overview
- 10.1.2 Company Insights
- 10.1.3 Business Breakdown
- 10.1.4 Product Benchmarking
- 10.1.5 Key Developments
- 10.1.6 Winning Imperatives
- 10.1.7 Current Focus & Strategies
- 10.1.8 Threat from Competition
- 10.1.9 SWOT Analysis
10.2 Merck KGAA
- 10.2.1 Company Overview
- 10.2.2 Company Insights
- 10.2.3 Business Breakdown
- 10.2.4 Product Benchmarking
- 10.2.5 Key Developments
- 10.2.6 Winning Imperatives
- 10.2.7 Current Focus & Strategies
- 10.2.8 Threat from Competition
- 10.2.9 SWOT Analysis
10.3 Bio-Rad Laboratories, Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Insights
- 10.3.3 Business Breakdown
- 10.3.4 Product Benchmarking
- 10.3.5 Key Developments
- 10.3.6 Winning Imperatives
- 10.3.7 Current Focus & Strategies
- 10.3.8 Threat from Competition
- 10.3.9 SWOT Analysis
10.4 Beckman Coulter, Inc.
- 10.4.1 Company Overview
- 10.4.2 Company Insights
- 10.4.3 Business Breakdown
- 10.4.4 Product Benchmarking
- 10.4.5 Key Developments
- 10.4.6 Winning Imperatives
- 10.4.7 Current Focus & Strategies
- 10.4.8 Threat from Competition
- 10.4.9 SWOT Analysis
10.5 Becton, Dickinson, and Company
- 10.5.1 Company Overview
- 10.5.2 Company Insights
- 10.5.3 Business Breakdown
- 10.5.4 Product Benchmarking
- 10.5.5 Key Developments
- 10.5.6 Winning Imperatives
- 10.5.7 Current Focus & Strategies
- 10.5.8 Threat from Competition
- 10.5.9 SWOT Analysis
10.6 Cell Signaling Technology, Inc.
- 10.6.1 Company Overview
- 10.6.2 Company Insights
- 10.6.3 Business Breakdown
- 10.6.4 Product Benchmarking
- 10.6.5 Key Developments
- 10.6.6 Winning Imperatives
- 10.6.7 Current Focus & Strategies
- 10.6.8 Threat from Competition
- 10.6.9 SWOT Analysis
10.7 MiltenyiBiotec
- 10.7.1 Company Overview
- 10.7.2 Company Insights
- 10.7.3 Business Breakdown
- 10.7.4 Product Benchmarking
- 10.7.5 Key Developments
- 10.7.6 Winning Imperatives
- 10.7.7 Current Focus & Strategies
- 10.7.8 Threat from Competition
- 10.7.9 SWOT Analysis
10.8 Roche Diagnostics
- 10.8.1 Company Overview
- 10.8.2 Company Insights
- 10.8.3 Business Breakdown
- 10.8.4 Product Benchmarking
- 10.8.5 Key Developments
- 10.8.6 Winning Imperatives
- 10.8.7 Current Focus & Strategies
- 10.8.8 Threat from Competition
- 10.8.9 SWOT Analysis
10.9 Qiagen N.V.
- 10.9.1 Company Overview
- 10.9.2 Company Insights
- 10.9.3 Business Breakdown
- 10.9.4 Product Benchmarking
- 10.9.5 Key Developments
- 10.9.6 Winning Imperatives
- 10.9.7 Current Focus & Strategies
- 10.9.8 Threat from Competition
- 10.9.9 SWOT Analysis
10.10 Qsonica, LLC
- 10.10.1 Company Overview
- 10.10.2 Company Insights
- 10.10.3 Business Breakdown
- 10.10.4 Product Benchmarking
- 10.10.5 Key Developments
- 10.10.6 Winning Imperatives
- 10.10.7 Current Focus & Strategies
- 10.10.8 Threat from Competition
- 10.10.9 SWOT Analysis